Polyclonal Antibodies Market Trends

Polyclonal Antibodies Market Trends

• The market is driven by several key factors that collectively contribute to its gains and prominence in the biomedical and pharmaceutical industries. Rising prevalence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases, acts as a significant driver. As the global burden of these diseases rises, the demand for versatile and effective tools for diagnosis and treatment, such as polyclonal antibodies.
   
• For instance, over 80 autoimmune diseases, including type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, impact nearly 4% of the global population. In the U.S. alone, autoimmune diseases rank as the third most prevalent cause of chronic illness, affecting 5-8% of the population, according to the National Institute of Health (NIH).
   
• Moreover, research collaboration and fundings contribute to expand the polyclonal antibodies industry. For instance, in October 2022, SAB Biotherapeutics has secured an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Within this partnership, Emergent will offer contract development and manufacturing (CDMO) services for the SAB's fully human polyclonal antibody production/products. This collaboration enables SAB to concentrate exclusively on the research and development of their polyclonal antibodies.